UNITED THERAPEUTICS Corp Form 8-K August 24, 2011

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 24, 2011

United Therapeutics Corporation

(Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction of Incorporation) **000-26301** (Commission File Number)

52-1984749 (I.R.S. Employer Identification Number)

1040 Spring Street Silver Spring, MD (Address of Principal Executive Offices)

20910 (Zip Code)

Registrant s telephone number, including area code: (301) 608-9292

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

0	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
0	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
0	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events

On August 24, 2011, United Therapeutics Corporation issued a press release announcing the results of its FREEDOM-C2 registration trial of oral treprostinil. A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01. Exhibits

(d) Exhibits

Exhibit No. Description of Exhibit

99.1 Press release dated August 24, 2011

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

UNITED THERAPEUTICS CORPORATION

Dated: August 24, 2011 By: /s/ Paul A. Mahon

Name: Paul A. Mahon Title: General Counsel

3

Exhibit Index

Exhibit No. Description of Exhibit

99.1 Press release dated August 24, 2011

4